Connect with us

Industry News

Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

Avatar

Published

on

default_cannabis_industry_cannamaps

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications.The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets.The study aims to show the potential for reduction or elimination of the use of opiates in patients, a major epidemic throughout North America.The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.TORONTO, Dec. 05, 2018 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia), subject to approval of the University of British Columbia where the proposed clinical trial will take place. The aim of the study is to examine and quantify the efficacy of Canntab products in decreasing the duration and quantity of postoperative use of opioid medications and in the management of preoperative pain. Dr. Garbuz shall be the Lead Investigator for the research study.The Company is seeking approval from UBC to conduct with Dr. Garbuz as lead investigator, a randomized, double-blind, placebo-controlled clinical trials to determine the efficacy of Canntab’s products in helping effectively treat pain in patients. The study will look at the use of Canntab tablets to treat pain after knee replacement surgery. Patient safety and tolerability will also be assessed.  Further, Canntab’s patent pending filing for addiction treatment therapy for opioids and other painkillers, and its specific proprietary tablet formulation, will be the starting point for the dosing delivery mechanism to be used in the study.Canntab advises that it will create the tablets for the study in Coburg, Ontario with FSD Pharma, a Licensed Producer under the ACMPR in furtherance of their collaboration and license agreement dated September 17, 2018.Zeeshan Saeed, President and Founder of FSD Pharma commented, “We are pleased that Canntab will be producing its tablets for this important study at our facility in Cobourg. The aim of this work is clearly in line with FSD Pharma’s direction and plans to develop pharmaceutical cannabinoid-based treatments for pain to counter the opioid crisis, including opioid abuse, dependence and overdose.”Dr. Don Garbuz will be overseeing the study as lead investigator pursuant to a consulting agreement to be entered into between Canntab and Dr. Garbuz.  Dr. Garbuz is a renowned orthopaedic surgeon and medical researcher, a Professor at the University of British Columbia and is credited with over 120 peer reviewed publications. Dr. Garbuz has been awarded the Hip Society Award for Best Research Paper four times; in 2009, 2011, 2013 and 2017.“I am excited to be partnering with Canntab to look at conducting a trial that will analyze the efficacy of cannabis as a replacement for opioids, in postoperative care of orthopedic surgical patients undergoing hip/knee replacements at the UBC Hospital. This study will help advance our understanding of the potential effects of cannabis as a treatment for pain and will become the basis for conducting future cannabinoid and pain management clinical trials,” said Dr. Don Garbuz, M.D. “This important study which aims to help us better understand the potential impact of cannabis as an alternative for opioids, so that patients might face better outcomes.”There is an opioid epidemic in the United States and Canada. The quality of life and addiction issues that stem from the widespread use of opioids is a major concern for individuals, communities, health care professionals and all levels of government. Most, if not all, patients undergoing total knee and hip arthroplasty use opioid medication to control their pain postoperatively. Their opioid usage is proving to be detrimental to overall health outcomes in some patients, and sometimes fatal. It is not uncommon for patients to misuse these medications after surgery, with nearly 5% of previously opiate-naïve patients becoming chronic abusers. A study from The Centers for Disease Control and Prevention (CDC) found that opiate prescriptions with medication supplies lasting greater than 8 days increased the likelihood of long-term abuse at 1 year (references below).The financial arrangement calls for an initial upfront fee to create the clinical protocol while securing the participation and, required approvals of the clinical trial by UBC and the independent team comprising the Ethics  Committee. Following those approvals, funds will be disbursed partially on certain milestones being achieved.  The total cost of the study is estimated at approximately $600,000 with an anticipated time frame to complete of between 12 to 18 months.About CanntabCanntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL.For further information contact:Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca
Forward Looking StatementsCertain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.SourcesSabatino MJ, Kunkel ST, Ramkumar DB, Keeney BJ, Jevsevar DS. Excess Opioid Medication and Variation in Prescribing Patterns Following Common Orthopaedic Procedures. J Bone Joint Surg Am 2018;100:180-8.Inacio MC, Hansen C, Pratt NL, Graves SE, Roughead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open 2016;6:e010664,2015-010664.Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain 2016;157:1259-65.

Original story can be found at: http://globenewswire.com/news-release/2018/12/05/1662369/0/en/Canntab-Enters-Into-a-Binding-Term-Sheet-With-Leading-Orthopaedic-Surgeon-Dr-Don-Garbuz-M-D-for-a-Clinical-Research-Trial-of-Canntab-s-Tablets.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

AGCO releases results of the second cannabis lottery: 42 applicants notified to apply for a cannabis Retail Store Authorization in Ontario

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, Aug. 21, 2019 (GLOBE NEWSWIRE) — The Alcohol and Gaming Commission of Ontario (AGCO) has released the results of the cannabis retail store lottery draw it held on August 20, 2019. The lottery provided those who met pre-qualification requirements for one of the 42 new store authorizations announced by the Government of Ontario on July 3, 2019, an opportunity to be selected to apply for one.
4,864 eligible expressions of interest were included in the lottery draw, which was overseen by a third-party fairness monitor. The AGCO has notified the following 42 selected applicants that they may now apply for a cannabis Retail Operator Licence and a Retail Store Authorization. Applicants have until August 28, 2019 to do so, at which point the AGCO will undertake its full eligibility and licensing review. The AGCO will only licence applicants and authorize stores that meet all legal and regulatory requirements.SELECTED APPLICANTS AND THEIR PROPOSED STORE LOCATIONSEast Region:GTA Region:North Region:Toronto Region:West Region:ADDITIONAL INFORMATIONAllocation lottery resultsSummary of lottery entries received by regionCannabis Retail Store Allocation Lottery RulesRegistrar’s Standards for Cannabis Retail StoresAbout the AGCO
The Alcohol and Gaming Commission of Ontario (AGCO) is an Ontario provincial regulatory agency reporting to the Ministry of the Attorney General (MAG). The agency was established on February 23, 1998 under the Alcohol, Cannabis and Gaming Regulation and Public Protection Act, 1996.
The AGCO is responsible for regulating the alcohol, lottery and gaming, horse racing and private cannabis retail sectors in accordance with the principles of honesty and integrity, and in the public interest.Media Contact:
Raymond Kahnert, Senior Advisor, Communications
(416) 326-3202, media@agco.ca 
FACT SHEETOn July 3, 2019, the Government of Ontario announced 50 new cannabis retail store authorizations would be made available. Of these 50 new stores, the AGCO will allocate up to 42 authorizations to applicants selected by lottery and eight to stores on First Nations reserves.Applicants who wished to participate in this lottery had to meet pre-qualification requirements, including confirmation from a bank, credit union, or caisse populaire that the applicant has the financial capacity to obtain $250,000 in cash or cash equivalents; confirmation from a bank, credit union, or caisse populaire that the applicant can obtain a Standby Letter of Credit in the amount of $50,000 within five business days of being notified of their selection; confirmation that the applicant has secured a suitable retail space, which will be available to them for operating a cannabis retail store no later than October 2019The required bank letters were provided to the lottery applicants by over 25 banking institutionsOnce the AGCO receives Retail Store Authorization applications from those selected in the lottery, residents of the community in which a store is proposed to be located will have an opportunity to provide written submissions if they believe the location of the store is not in the public interest, as defined by Ontario Regulation 468/18 made under the Cannabis Licence Act, 2018It is anticipated that stores will begin to open starting in October 2019, as they are readyThe AGCO has placed the applicants not selected in the lottery on Wait Lists for each Region, based on the order in which they were drawn. Applicants on the Wait List will be moved to the selected list if those ahead of them are found to be ineligible for a licence/authorization or are otherwise disqualifiedIn the future, if the Government proceeds with additional retail store allocations before moving to an open marketplace, any such allocations may be based on the results from this lottery

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/21/1904954/0/en/AGCO-releases-results-of-the-second-cannabis-lottery-42-applicants-notified-to-apply-for-a-cannabis-Retail-Store-Authorization-in-Ontario.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Infinity Supercritical Announces SDR Model X For Continuous Feed Hemp Oil Processing

Avatar

Published

on

default_cannabis_industry_cannamaps

MADISON, Wis., Aug. 21, 2019 (GLOBE NEWSWIRE) — Infinity Supercritical LLC is introducing its industrial scale hemp oil processors that use water to extract full spectrum oil in under a second. Our modular botanical oil processors can extract oil from your organic hemp, with a capacity of 10,000 lbs to 100,000 lbs per day. The continuous feed process is the only in the industry that uses water as the solvent, to produce a eco-extracted oil, that can be labeled with organic and green branding.
Less than 10 percent of the 2019 hemp crop will be processed at fall harvest from the lack of botanical extractors. Based on the deluge of calls we get from farmers, wanna-be processors, and equity groups, there will be a huge bottleneck at this years fall hemp harvest.Hemp became Federally legal in 2019, which had farmers scrambling to get crops in the ground, many at the last minute in late spring. The lack of coordinated state regulation nationwide has resulted in a patch-work of states under cultivation, some more than ten-fold increase in acreage planted from last year.While many smaller fly-by-night processors turn to ethanol extraction. If not done properly, it produces a poor quality full spectrum hemp CBD oil. A full spectrum oil provides the most benefits to the body. Many operators choose to use activated carbon to filter out the green bitter tasting chlorophyll, which unfortunately also filters out the CBDs. The consumer may not know the difference when purchasing full spectrum oil, aside from being turned off from lackluster results.The result? Much of the hemp crop will go unprocessed, and some will go into long term storage and degrade.Infinity Supercritical LLC offers innovative one-touch processing technology using water as the solvent, and a visionary future for clean and quality full spectrum hemp CBD oil extraction.  Please visit https://sonicextractor.com for more information.G. Giese | CEO | Infinity Supercritical LLC | greg@infinitysupercritical.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/21/1904928/0/en/Infinity-Supercritical-Announces-SDR-Model-X-For-Continuous-Feed-Hemp-Oil-Processing.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

CURE Pharmaceutical [OTCQB: CURR] Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms 

Avatar

Published

on

default_cannabis_industry_cannamaps

OXNARD, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, CUREfilm®.
“The agreement with Fytiko Farms is a crucial step in CURE’s effort to secure our CBD supply chain and also includes preferred pricing for CURE,” said Rob Davidson, CEO of CURE Pharmaceutical. “This puts CURE in a strategic position to further deliver on our mission to bring the best products to our customers and accelerates our product commercialization. Our next step will be securing a relationship with vendors for the extraction process leveraging our extraction patents.”The deal provides access to high-quality organic hemp extracts for use in CURE products through strain improvement, cannabinoid extraction process development, biomarker identification and quality control testing.“Partnering with an industry leader like CURE allows us to expand into more markets and grow our production capabilities,” said Joe Dan Rogers, CEO of Fytiko Farms. “This partnership supports our main business of growing hemp by providing a production hub for local farmers and marketing our high-quality hemp oil and other byproducts for use in CURE’s hemp-based products.”Fytiko Farms is an innovative company focused on industrial hemp production, cultivation, seed and clone production and sale and the processing and sale of the various by-products from the hemp plant. In 2019, Fytiko Farms was licensed to plant in Oklahoma, utilizing select varieties specifically targeted for their genetics.About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.About Fytiko Farms
Fytiko Farms is an innovative company focused on industrial Hemp cultivation, seed and clone production and sale and processing of the various byproducts from the Hemp plant. Fytiko Farms collaborates Murray State College to develop and promote new technologies through research, education, and collaboration in the creation of stable, reliable seed stock for industrial hemp and the cultivation of industrial hemp inside the State of Oklahoma as permitted by the Oklahoma Industrial Hemp Agriculture Pilot Program. Fytiko Farms is licensed to plant and cultivate up to 100 acres for 2019.
For more information about Fytiko Farms, please visit its website at www.fytikofarms.com.This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.Contact:
Ashley Ray
aray@olmsteadwilliams.com
310.824.9000 (office), 919.630.5508 (cell)

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/21/1904761/0/en/CURE-Pharmaceutical-OTCQB-CURR-Takes-First-Step-To-Secure-Hemp-CBD-Supply-Chain-by-Partnering-with-Fytiko-Farms.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending